Clinical Management of End-Stage Renal Disease and Hemodialysis Patients with Diabetes

Dear Colleagues,

The rapid increase in the number of diabetic patients with end-stage renal disease (ESRD) in conservative or dialysis treatment is a global problem in the world, not only in western countries but also in Asia, Africa, and South America. This diabetic population is aged more than 65 years, largely due to the aging population of type II diabetes. Diabetic nephropathy is a chronic disease, most often progressive, and hence serious for associated comorbidities such as peripheral vascular ischemic disease, heart arrhythmia, and pulmonary chronic disease. Most patients undergo in-center hemodialysis (HD), and few patients undergo PD and kidney transplantation. To best deal with the clinical management of diabetics with severe renal failure, many questions remain open, such as the use in these patients of the new oral antidiabetic drugs (SGLT2i, GLP1RA and DDP-4i) or of NOACs for atrial fibrillation. In addition, we must consider during the conservative treatment the role of the diet, of metformin and the risk of lactic acidosis, and later the type and modality of dialysis, the organization of care, and all of the new tools that technology offers for improving hemodynamic stability during dialysis sessions. Therefore, besides nephrologists and diabetologists, many specialists such as cardiologists, physicians, nurses, clinical engineers, pharmacists, and nutritionists could be involved and contribute with their expertise to this Special Issue on “Clinical Management of End-Stage Renal Disease and Hemodialysis Patients with Diabetes”.

The present work aims to update clinicians by summarizing the remarkable progress made recently in the care of diabetic patients with ESRD.

Prof. Dr. Filippo Mariano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.